Understanding Sjogren’s Syndrome

Sjogren’s syndrome is a medical condition that affects the exocrine glands, leading to dry mucosal surfaces. It can either be primary or secondary to other connective tissue disorders, such as rheumatoid arthritis. The condition is more common in females, with a ratio of 9:1. Patients with Sjogren’s syndrome have a higher risk of developing lymphoid malignancy, which is 40-60 times more likely than the general population.

The symptoms of Sjogren’s syndrome include dry eyes, dry mouth, vaginal dryness, arthralgia, Raynaud’s, myalgia, sensory polyneuropathy, recurrent episodes of parotitis, and subclinical renal tubular acidosis. To diagnose the condition, doctors may perform a Schirmer’s test to measure tear formation, as well as check for the presence of rheumatoid factor, ANA, anti-Ro (SSA) antibodies, and anti-La (SSB) antibodies.

Management of Sjogren’s syndrome involves the use of artificial saliva and tears, as well as medications like pilocarpine to stimulate saliva production. It is important for patients with Sjogren’s syndrome to receive regular medical care and monitoring to manage their symptoms and reduce the risk of complications.

Importance of Checking TPMT Levels Before Starting Azathioprine

Prior to initiating treatment with azathioprine, it is crucial to check the patient’s blood for thiopurine methyltransferase (TPMT) levels. Azathioprine is metabolized into 6-mercaptopurine (6-MP) in the body, which can either be converted into inactive 6-methyl mercaptopurine or methylated into active compounds by TPMT. In Caucasians, 89% of individuals have normal or high levels of TPMT, while 11% have low levels and 0.3% are deficient in TPMT. Administering azathioprine to those who are TPMT deficiency can lead to severe side effects such as myelosuppression.

Patients with normal or high levels of TPMT can safely begin treatment with azathioprine. However, those with low levels of TPMT should be closely monitored and given low doses of azathioprine under expert supervision. Therefore, it is essential to check TPMT levels before starting azathioprine to ensure the safety and efficacy of the treatment.

Polymyalgia Rheumatica/Temporal Arteritis: Symptoms and Treatment

Polymyalgia rheumatica/temporal arteritis is a condition that can cause a variety of symptoms. It may present with predominantly polymyalgia symptoms such as muscle pain and stiffness, or arteritis symptoms such as headaches, scalp tenderness, and jaw claudication. Systemic features like fever, malaise, and weight loss may also be present. Weakness is not a typical feature, but it may be apparent due to pain or stiffness with weight loss. The ESR (erythrocyte sedimentation rate) is usually very high in this condition.

Temporal arteritis is a serious complication of this condition that can result in blindness. It is important to note that temporal arteritis is a vasculitis that affects medium and large-sized arteries throughout the body, not just the temporal artery. The superficial temporal artery supplies the orbit of the eye and is a branch of the external carotid artery, while the ophthalmic artery supplies the majority of the blood to the eye itself and is a branch of the internal carotid artery. Inflammation and narrowing of the temporal artery can cause blindness.

If temporal arteritis is suspected, it must be treated with high-dose steroids. This condition is a reminder that prompt diagnosis and treatment are crucial to prevent serious complications.

Double-stranded DNA antibody (dsDNA) inhibitor

Drug-induced lupus is a condition that differs from systemic lupus erythematosus in that it does not typically involve renal or nervous system complications. This condition can be resolved by discontinuing the medication that caused it. Symptoms of drug-induced lupus include joint and muscle pain, skin rashes (such as a malar rash), and pleurisy. Patients with this condition will test positive for ANA, but negative for dsDNA. Anti-histone antibodies are found in 80-90% of cases, while anti-Ro and anti-Smith are only present in around 5%. The most common causes of drug-induced lupus are procainamide and hydralazine, while less common causes include isoniazid, minocycline, and phenytoin.

Discitis patients should undergo a whole spine MRI as it is the most sensitive diagnostic test. MRI is preferred due to its high sensitivity and specificity, and can differentiate between different types of infections and neoplastic processes. While bone and WBC scans are more sensitive than plain film and CT, they lack specificity. Prior to starting antibiotics, a CT guided biopsy should be performed unless there is a positive blood culture that matches the clinical presentation or the patient is unstable/septic.

Understanding Discitis: Causes, Symptoms, Diagnosis, and Treatment

Discitis is a condition that occurs when there is an infection in the intervertebral disc space. This can lead to serious complications such as sepsis or an epidural abscess. The most common cause of discitis is bacterial, with Staphylococcus aureus being the most common culprit. However, it can also be caused by viral infections like TB or be aseptic in nature.

Symptoms of discitis include back pain, pyrexia, rigors, and sepsis. In some cases, there may also be neurological symptoms like changing lower limb neurology if an epidural abscess develops. To diagnose discitis, imaging tests like MRI are used, and a CT guided biopsy may be required to guide antimicrobial treatment.

The standard treatment for discitis involves six to eight weeks of intravenous antibiotic therapy. The choice of antibiotic depends on various factors, with the most important being the identification of the organism causing the infection through a positive culture. Complications of discitis include sepsis and epidural abscess, which can be life-threatening.

It is important to assess the patient for endocarditis, as discitis is usually due to haematogenous seeding of the vertebrae, implying that the patient has had a bacteraemia and seeding could have occurred elsewhere. Understanding the causes, symptoms, diagnosis, and treatment of discitis is crucial in managing this condition and preventing serious complications.

Understanding Paget’s Disease of the Bone

Paget’s disease of the bone is a condition characterized by increased and uncontrolled bone turnover. It is believed to be caused by excessive osteoclastic resorption followed by increased osteoblastic activity. Although it is a common condition, affecting around 5% of the UK population, only 1 in 20 patients experience symptoms. The most commonly affected areas are the skull, spine/pelvis, and long bones of the lower extremities.

Several factors can predispose an individual to Paget’s disease, including increasing age, male sex, living in northern latitudes, and having a family history of the condition. Symptoms of Paget’s disease include bone pain, particularly in the pelvis, lumbar spine, and femur. In untreated cases, patients may experience bowing of the tibia or bossing of the skull.

To diagnose Paget’s disease, doctors may perform blood tests to check for elevated levels of alkaline phosphatase (ALP), a marker of bone turnover. Other markers of bone turnover, such as procollagen type I N-terminal propeptide (PINP), serum C-telopeptide (CTx), urinary N-telopeptide (NTx), and urinary hydroxyproline, may also be measured. X-rays and bone scintigraphy can help identify areas of active bone lesions.

Treatment for Paget’s disease is typically reserved for patients experiencing bone pain, skull or long bone deformity, fractures, or periarticular Paget’s. Bisphosphonates, such as oral risedronate or IV zoledronate, are commonly used to manage the condition. Calcitonin may also be used in some cases. Complications of Paget’s disease can include deafness, bone sarcoma, fractures, skull thickening, and high-output cardiac failure.

Differential Diagnosis for a Patient with Skin Lesions, Proteinuria, and Neurological Symptoms

Polyarteritis nodosa (PAN) is a possible diagnosis for a patient presenting with erythematous nodules, livedo reticularis, mononeuritis multiplex, and kidney involvement. This condition is often associated with hepatitis B infection, which can be confirmed by the presence of hepatitis B surface antigen. Idiopathic thrombocytopenic purpura, which typically presents with bruising, petechiae, and epistaxis, is less likely to explain the proteinuria and is more commonly seen in children. Henoch–Schönlein purpura (HSP) can cause a purpuric rash in the lower extremities and buttocks, as well as renal involvement, but it does not typically present with mononeuritis multiplex. Kaposi’s sarcoma is unlikely without HIV and would not explain the neurological symptoms. Impaired coagulation secondary to liver cirrhosis is an unlikely diagnosis in the absence of chronic liver disease and would not account for the neurological symptoms.

If NSAIDs and colchicine cannot be used due to contraindications or intolerance, the next option for treating gout is a steroid. In this particular case, the most suitable treatment for the patient would be oral prednisolone as he has gout affecting a small joint and has relative contraindications to NSAIDs and colchicine due to asthma, previous intolerance of colchicine, and renal disease. Febuxostat is not a suitable choice as it is a medication used for gout prophylaxis. Another option for treatment would be a steroid injection directly into the affected joint, but not an intramuscular steroid injection.

Gout is caused by chronic hyperuricaemia and is managed acutely with NSAIDs or colchicine. Urate-lowering therapy (ULT) is recommended for patients with >= 2 attacks in 12 months, tophi, renal disease, uric acid renal stones, or prophylaxis if on cytotoxics or diuretics. Allopurinol is first-line ULT, with a delayed start recommended until inflammation has settled. Lifestyle modifications include reducing alcohol intake, losing weight if obese, and avoiding high-purine foods. Other options for refractory cases include febuxostat, uricase, and pegloticase.

Treatment for Generalised Granulomatosis with Polyangiitis

This patient has been diagnosed with active generalised Granulomatosis with polyangiitis based on clinical and serological evidence. To confirm the diagnosis and guide treatment, a renal biopsy should be performed before starting any long-term treatment. Azathioprine or methotrexate are not effective in inducing remission for this patient. The recommended pharmacotherapy for her includes IV methylprednisolone (1 gm/day for three days) and cyclophosphamide. If necessary, IV methylprednisolone can be started before the renal biopsy.

Overall, it is important to accurately diagnose and treat generalised Granulomatosis with polyangiitis to prevent further complications and improve the patient’s quality of life.

Scleroderma and Renal Crisis

Scleroderma is a rare autoimmune disease that affects the skin and internal organs. In some cases, it can lead to a condition called scleroderma renal crisis (SRC), which occurs in up to 10% of cases. SRC is characterized by rapid onset renal failure, malignant hypertension, micro-angiopathic haemolytic anaemia with schistocytes, and symptoms of fluid overload.

Patients with diffuse cutaneous systemic sclerosis and pulmonary fibrosis are at a higher risk of developing SRC. Other risk factors include recent onset scleroderma (less than three years), corticosteroid use (prednisolone more than 15 mg/day), and involvement of other systems. The underlying pathology of SRC is vasospasm, and treatment involves starting ACE inhibitors.

It is important to note that scleroderma does not typically associate with interstitial nephritis, glomerulonephritis, and acute tubular necrosis. Early recognition and treatment of SRC is crucial to prevent irreversible kidney damage and improve patient outcomes.